Get the Stockscreener App
2.60
1.89%
-0.05
Pre-market:
2.62
0.02
+0.77%
Black Diamond Therapeutics Inc stock is traded at $2.60, with a volume of 757.95K.
It is down -1.89% in the last 24 hours and up +11.59% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
See More
Previous Close:
$2.65
Open:
$2.65
24h Volume:
757.95K
Relative Volume:
1.08
Market Cap:
$148.98M
Revenue:
$70.00M
Net Income/Loss:
$22.37M
P/E Ratio:
6.8349
EPS:
0.3804
Net Cash Flow:
$29.61M
1W Performance:
-12.46%
1M Performance:
+11.59%
6M Performance:
-32.82%
1Y Performance:
+52.94%
1-Day Range:
$2.535
$2.65
1-Week Range:
$2.535
$3.085
52-Week Range:
$1.46
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.60 | 148.98M | 70.00M | 22.37M | 29.61M | 0.3804 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-25 | Resumed | Piper Sandler | Overweight |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Implied volatility surging for Black Diamond Therapeutics stock options - MSN
HC Wainwright Issues Positive Forecast for BDTX Earnings - MarketBeat
Why is Black Diamond (BDTX) up 19.3% since last earnings report? - MSN
[ARS] Black Diamond Therapeutics, Inc. SEC Filing - Stock Titan
Black Diamond Therapeutics (BDTX) outlines 2026 virtual meeting and Say-on-Pay votes - Stock Titan
BDTX Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Given New $11.00 Price Target at BTIG Research - MarketBeat
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Implied Volatility Surging for Black Diamond Therapeutics Stock Options - Zacks Investment Research
BDTX: What silevertinib data say about EGFR NSCLC upside - MSN
Will Upcoming Catalysts Help Black Diamond Investors Breathe Easy? - RTTNews
Black Diamond stock: Weighing catalysts vs. concentration - MSN
Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy - MarketBeat
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize - TradingView
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right - Yahoo Finance
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks - TradingView
BlackDiamond (BDTX) Stock: Technical Momentum Review | Q4 2025: Earnings Fall ShortBuyback Report - Xã Châu Thành
BDTX (Black Diamond Therapeutics Inc.) shares rise nearly 8 percent even as fourth quarter 2025 earnings fall well below analyst estimates.Community Sell Signals - UBND thành phố Hải Phòng
Black Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual Meeting - Quiver Quantitative
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting - ChartMill
Lung cancer drug data from Black Diamond gets ASCO oral slot - Stock Titan
BlackDiamond (BDTX) Stock Options Volume (Grinds Higher) 2026-04-20High Yield Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
BlackDiamond (BDTX) Stock: Why Day Traders Love It (+4.79%) 2026-04-18Social Momentum Signals - UBND thành phố Hải Phòng
Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program - MSN
Black Diamond Sued Over Patented Cancer Drug Discovery Methods - Bloomberg Law News
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? - Yahoo Finance
BlackDiamond (BDTX) Stock Adds to Position (Buying Pressure) 2026-04-15Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
Trading Action: Will Black Diamond Therapeutics Inc benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - baoquankhu1.vn
Volatility Watch: Will Black Diamond Therapeutics Inc benefit from AI trends2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Black Diamond Therapeutics Receives 'Moderate Buy' Rating from Analysts - National Today
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Market Fear: Does Black Diamond Therapeutics Inc outperform in volatile marketsGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Invesco Senior Loan Fund's Black Diamond Therapeutics Inc(BDTX) Holding History - GuruFocus
Investment Recap: How does Black Diamond Therapeutics Inc score in quality rankingsWeekly Investment Summary & Long-Term Safe Return Strategies - baoquankhu1.vn
Risk Recap: Is Black Diamond Therapeutics Inc part of any ETFDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
BDTX: Insights from Silevertinib Data on EGFR NSCLC Growth Potential - Bitget
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026 - TradingView
Black Diamond Stock: Weighing Catalysts vs. Concentration - Yahoo Finance
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside - TradingView
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):